MarketInOut Stock Screener Log In | Sign Up

Evolus Inc

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 10/30/2026
Evolus Inc stock price and volume chart

Company Profile

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization485.47 mln
Float57.84 mln
Earnings Date11/04/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-2.67
Likely reliable

Relative Strength

81 / 100
Strongly outperforming

Pre-Tax Margin

-11%
Loss-making

ROE

123
Extraordinary

Altman Z-Score

-1.41
Deeply distressed

Business Description

Evolus is a US-based aesthetics company that sells directly to consumers in the United States, Canada, Europe, and Australia. Its main product, Jeuveau, is an injectable treatment that temporarily reduces the appearance of frown lines between the eyebrows. The company also offers Evolysse, a range of injectable fillers designed to restore volume and smooth the appearance of the face, lips, and eyes. Founded in 2012, Evolus operates out of Newport Beach, California.

Key Fundamentals

EPS-0.53
ROE123
RPS4.86
ROIC-15.00
ROA-15.03
Interest Cover-1.43
EBITDA, mln-7.21
EV / EBITDA-84.03
EV / EBIT-34.70
Revenue, mln316
EV / Revenue1.91

Quote Details

Last 7.35
Change -0.17 (-2.26%)
Open 7.48
Volume 793,382
Turnover 5,831,358
Average Volume 777,537

Financial Ratios

Pre-Tax Profit Margin-11
Current Ratio1.70
Price / Sales1.52

Financial Strength

Altman Z-Score-1.41
Piotroski F-Score 3 / 9
Beneish M-Score-2.67
Short Ratio8.44
Short % of Float9.82

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 4.85% 88 / 100   
1 Month -4.42% 41 / 100   
2 Months 18.93% 92 / 100   
6 Months 37.9% 94 / 100   
1 Year 7.14% 62 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog